Drug intelligence / Profile preview

high dose human umbilical cord-derived mesenchymal stem cells

Development stage: Unknown
Lead developer: Sclnow Biotechnology
Modality: Stem Cell Therapies → Cell Therapies
Administration: Intravenous, Intrathecal, Subcutaneous

Overview

High dose human umbilical cord-derived mesenchymal stem cells (hUC-MSCs) are a cell-based therapy derived from umbilical cord tissue. These cells possess immunomodulatory, anti-inflammatory, and regenerative properties. They are being investigated for various conditions including multiple sclerosis, bronchopulmonary dysplasia, pulmonary fibrosis, and knee osteoarthritis. The high dose typically refers to concentrations ranging from 3.0 × 10^7 cells/kg to 5.0 × 10^7 cells/kg, compared to low doses which are typically around 1.0 × 10^6 cells/kg to 3.0 × 10^6 cells/kg.

Other names: high dose hUC-MSCs

Beyond the preview

Go deeper on high dose human umbilical cord-derived mesenchymal stem cells.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on high dose human umbilical cord-derived mesenchymal stem cells.

Explore the full profile